X4 Pharmaceuticals reported earnings of -$ 0.16 per XFOR share on Nov 5, 2026, falling short of analysts' expectations by
| Report Date | Nov 5, 2026 |
|---|---|
| Forecasted EPS | -$ 0.17 |
| Earnings Per Share (Surprise) | -$ 0.16 (+$ 0.008) |
| Last Year's EPS | -$ 1.09 |
| EPS YoY Change |
Out of the last 42 earnings reporting periods, X4 Pharmaceuticals beat analysts’ expectations 14 times and fell short of expectations 22 time(s). X4 Pharmaceuticals reported earnings per share of -$ 0.16 in the last report surpassing an estimated EPS of -$ 0.17 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 5, 2026 | -$ 0.17 | -$ 0.16 | -$ 0.22 | |
| Nov 4, 2026 | -$ 0.17 | -$ 0.16 | -$ 0.69 | |
| Aug 7, 2026 | -$ 0.18 | -$ 0.13 | -$ 3.47 | |
| May 6, 2026 | -$ 0.20 | -$ 0.16 | $ 0.04 | |
| Mar 17, 2026 | -$ 0.36 | -$ 0.22 | -$ 6.01 | |
| Nov 5, 2025 | -$ 0.79 | -$ 0.69 | -$ 5.41 | |
| Aug 8, 2025 | -$ 4.53 | -$ 3.47 | -$ 2.10 | |
| May 1, 2025 | -$ 4.13 | $ 0.04 | -$ 7.81 | |
| Mar 25, 2025 | -$ 5.11 | -$ 6.01 | -$ 3.00 | |
| Nov 13, 2024 | -$ 5.11 | -$ 5.41 | -$ 0.30 | |
| Aug 8, 2024 | -$ 0.21 | -$ 2.10 | -$ 9.91 | |
| May 7, 2024 | -$ 0.17 | -$ 7.81 | -$ 4.80 | |
| Mar 21, 2024 | -$ 0.15 | -$ 3.00 | -$ 8.71 | |
| Nov 9, 2023 | -$ 0.15 | -$ 0.30 | -$ 7.81 | |
| Aug 10, 2023 | -$ 0.17 | -$ 9.91 | -$ 17.96 | |
| May 4, 2023 | -$ 0.22 | -$ 4.80 | -$ 0.72 | |
| Mar 21, 2023 | -$ 0.27 | -$ 8.71 | -$ 37.14 | |
| Nov 3, 2022 | -$ 0.30 | -$ 7.81 | -$ 22.82 | |
| Aug 4, 2022 | -$ 0.64 | -$ 17.96 | -$ 22.22 | |
| May 12, 2022 | -$ 0.61 | -$ 0.72 | -$ 39.04 |
X4 Pharmaceuticals’s stock was trading at $ 3.24 on Nov 4, 2026 a day before the last earnings report was released.Following the release of the earnings report, XFOR’s price decreased to $ 3.18 on Nov 6, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 5, 2026 | -$ 0.16 | $ 3.24 | $ 3.18 | |
| Nov 4, 2026 | -$ 0.16 | $ 3.17 | $ 3.07 | |
| Aug 7, 2026 | -$ 0.13 | $ 4.17 | $ 4.25 | |
| May 6, 2026 | -$ 0.16 | $ 4.20 | $ 4.29 | |
| Mar 17, 2026 | -$ 0.22 | $ 3.56 | $ 4.05 | |
| Nov 5, 2025 | -$ 0.69 | $ 3.97 | $ 3.51 | |
| Aug 8, 2025 | -$ 3.47 | $ 1.46 | $ 1.42 | |
| May 1, 2025 | $ 0.04 | $ 4.31 | $ 3.73 | |
| Mar 25, 2025 | -$ 6.01 | $ 8.85 | $ 8.08 | |
| Nov 13, 2024 | -$ 5.41 | $ 17.76 | $ 12.30 | |
| Aug 8, 2024 | -$ 2.10 | $ 18.93 | $ 18.90 | |
| May 7, 2024 | -$ 7.81 | $ 36.00 | $ 31.20 | |
| Mar 21, 2024 | -$ 3.00 | $ 30.60 | $ 43.80 | |
| Nov 9, 2023 | -$ 0.30 | $ 22.22 | $ 22.51 | |
| Aug 10, 2023 | -$ 9.91 | $ 49.20 | $ 38.40 | |
| May 4, 2023 | -$ 4.80 | $ 44.40 | $ 51.00 | |
| Mar 21, 2023 | -$ 8.71 | $ 26.61 | $ 25.65 | |
| Nov 3, 2022 | -$ 7.81 | $ 58.80 | $ 55.50 | |
| Aug 4, 2022 | -$ 17.96 | $ 38.70 | $ 36.00 | |
| May 12, 2022 | -$ 0.72 | $ 31.50 | $ 36.00 |
X4 Pharmaceuticals released its most recent earnings reports in November 2026, November 2026, August 2026, May 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
X4 Pharmaceuticals beat analysts’ expectations during the last earnings period by
